Navigation Links
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Date:8/19/2009

n early significant reduction in distant metastases versus tamoxifen at a median follow-up of 26, 51 and 76 months.

"Femara is the only aromatase inhibitor to demonstrate consistent, early and significant reduction in risk of distant metastases," said Alessandro Riva, MD, Global Head Oncology Development, Novartis Oncology. "Based on these results, starting with Femara monotherapy for five years in the adjuvant setting instead of tamoxifen may offer breast cancer patients the opportunity for a better outcome."

Study details

This Phase III, randomized, double-blind, controlled clinical trial enrolled more than 8,000 postmenopausal women with early breast cancer in 27 countries[2].

Patients were randomly assigned one of four treatment regimens: (1) five years of tamoxifen only; (2) five years of Femara only; (3) two years of tamoxifen followed by three years of Femara; (4) two years of Femara followed by three years of tamoxifen.

The primary endpoint of the study was disease-free survival, defined as the time from randomization to the first of any of the following events: recurrence at local, regional, or distant sites; a new invasive cancer in the contralateral breast; any second, non-breast cancer; or death without a previous cancer event. Other endpoints included time to breast cancer recurrence, time to distant breast cancer recurrence and overall survival.

In 2005, following initial results showing superiority of Femara monotherapy over tamoxifen monotherapy in improving disease-free survival and reducing the risk of recurrence, the tamoxifen-only treatment arm was unblinded and approximately one quarter of those patients selectively crossed over to Femara treatment. The other three treatment arms remained blinded. Subsequent analyses were designed to estimate the extent to which the crossover affected the comparative benefit of Femara.


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... July 24, 2014  Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the first ... quarter overview: , Revenues of $47.5 million, up ... EPS of $0.21, up 50% over last year,s comparable ... revenues of $7.2 million, up 20% over last year,s ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Feb. 1, 2011 /PRNewswire-Asia-FirstCall/ --  China Medicine Corporation ... "Company"), a leading manufacturer, developer and distributor of ... health products in the People,s Republic of China, ... manufacturing license from the Chinese Ministry of Agriculture ...
... 2011 Stryker Corporation (NYSE: SYK ) ... of its OP-1 product family, which includes OP-1 Implant, ... bone applications. The transaction also includes the sale of ... Stryker is one of the world,s leading medical technology ...
Cached Medicine Technology:China Medicine Corporation Receives Manufacturing License for rADTZ 2China Medicine Corporation Receives Manufacturing License for rADTZ 3
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer ... casual party dresses . According to the company’s ... now offered at discounted prices, up to 59% off. ... August 04. , Most of the casual party ... market. They are popular for special designs, delicate craftsmanship ...
(Date:7/24/2014)... at night, which shuts off nighttime production of the ... a widely used breast cancer drug, says a new ... The study, "Circadian and Melatonin Disruption by Exposure to ... in Breast Cancer," published in the journal Cancer ... is vital to the success of tamoxifen in treating ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, 2014 (HealthDay News) ... wrong, according to a small study that asked boys what they ... between the ages of 14 and 16, researchers found that most ... and trust. Very few boasted about sexual conquests or saw sex ... "In our culture, we have lots of assumptions about how ...
(Date:7/24/2014)... Pools and beaches are the place to ... dangerous, especially for small children, so Amica Insurance ... to the Centers for Disease Control and Prevention, children between ... for water-related injuries and deaths. It’s important to know the ... Amica is offering the following tips from the American Red ...
Breaking Medicine News(10 mins):Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... suggests ways for FDA to beef up its oversight, , ... misled by the health claims made on the packaging of ... Institute of Medicine, because those claims do not undergo the ... A box of cereal that proclaims the breakfast food will ...
... ... with massage therapy , ... Scottsdale, AZ (PRWEB) May 12, 2010 -- Fibromyalgia has quickly gone from being ... conditions in American medicine. New treatments, medications and preventions are being developed every year ...
... ... with International Medical Group® (IMG®) to serve overseas missionaries. Each year Good ... focus is caring and honest service. IMG serves the needy in our ... mission sending organizations. Good Neighbor Insurance and IMG are particularly proud of ...
... disagree whether behavior describes a true addict , WEDNESDAY, May ... real problem in some people, causing them to engage in ... , The career of professional golfer Tiger Woods took a ... dozen women. Former New York Mets general manager Steve Phillips ...
... ... video conferencing solutions , ... Buffalo, NY (PRWEB) May 12, 2010 -- VoIP Supply, LLC North America’s leading ... introduction of video conferencing solutions to its base of over 75,000 customers. The initial ...
... “Choose ... ... -- Addressing the country’s obesity crisis, President Obama has declared May to be National ... attention to this complex problem. President Obama, in his proclamation, is asking ...
Cached Medicine News:Health News:Health Claims on Foods May Not Be Well-Grounded 2Health News:Health Claims on Foods May Not Be Well-Grounded 3Health News:Massage Envy Offers Relief for Fibromyalgia Sufferers 2Health News:Massage Envy Offers Relief for Fibromyalgia Sufferers 3Health News:Serving the World With Specialized Insurance for Missionaries 2Health News:Serving the World With Specialized Insurance for Missionaries 3Health News:Serving the World With Specialized Insurance for Missionaries 4Health News:The 'Reality' of Sex Addiction Stirs Debate 2Health News:The 'Reality' of Sex Addiction Stirs Debate 3Health News:VoIP Supply Launches Video Conferencing Solutions 2Health News:Dealtaker.com Shows Support for White House National Health and Fitness Initiatives 2
... mini-cells has always distinguished itself by ... tradition continues with the patented XCell ... gel tension wedge in place of ... models makes the XCell SureLock and ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... unit ideal for use in laboratories with low ... set at 12 rpm , Temperature control ... capacity of four 35 x 150mm bottles, eight ... , Consistent, repeatable results achieved with microprocessor ...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Medicine Products: